Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of liver damage and alteration of hepatic enzymes. NAFLD is strongly associated with metabolic syndrome and obesity. It is characterized by fat accumulation in the liver that may progress throughout hepatic steatosis and inflammation (non-alcoholic steatohepatitis [NASH]) toward cirrhosis and liver failure. In the last decade several studies suggested that NAFLD is an independent cardiovascular risk factor that increases cardiovascular mortality. At present, several studies investigating possible therapeutic approaches are ongoing. The present review is focused on the current and promising treatments of NAFLD.
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Cardiovascular & Hematological Disorders-Drug Targets
Title: Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
Volume: 9 Issue: 4
Author(s): Alessandra Quercioli, Fabrizio Montecucco and Francois Mach
Affiliation:
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of liver damage and alteration of hepatic enzymes. NAFLD is strongly associated with metabolic syndrome and obesity. It is characterized by fat accumulation in the liver that may progress throughout hepatic steatosis and inflammation (non-alcoholic steatohepatitis [NASH]) toward cirrhosis and liver failure. In the last decade several studies suggested that NAFLD is an independent cardiovascular risk factor that increases cardiovascular mortality. At present, several studies investigating possible therapeutic approaches are ongoing. The present review is focused on the current and promising treatments of NAFLD.
Export Options
About this article
Cite this article as:
Quercioli Alessandra, Montecucco Fabrizio and Mach Francois, Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/1871529X10909040261
DOI https://dx.doi.org/10.2174/1871529X10909040261 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
Current Cardiology Reviews Life-Threatening Respiratory Syncytial Virus Disease in Children
Current Respiratory Medicine Reviews Material-Based Engineering Strategies for Cardiac Regeneration
Current Pharmaceutical Design Intimal Hyperplasia in Murine Models
Current Drug Targets The Complementary Roles of Imaging and ‘Omics’ for Future Anti-Atherosclerotic Drug Development
Current Pharmaceutical Design Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism NPY and Cardiac Diseases
Current Topics in Medicinal Chemistry Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species
Anti-Infective Agents in Medicinal Chemistry The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Progress and Prospects of Stem Cells in Treatment of Drug Resistant Tuberculosis
Current Respiratory Medicine Reviews Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry Antioxidative Properties of Flavonoids
Current Organic Chemistry Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity
Current Drug Targets Nitric Oxide Synthase Function in Exercise
Current Enzyme Inhibition Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting
Current Pharmaceutical Design